Metagenes Associated with Survival in Non-Small Cell Lung Cancer

Abstract

NSCLC (non-small cell lung cancer) comprises about 80% of all lung cancer cases worldwide. Surgery is most effective treatment for patients with early-stage disease. However, 30%–55% of these patients develop recurrence within 5 years. Therefore, markers that can be used to accurately classify early-stage NSCLC patients into different prognostic groups may be helpful in selecting patients who should receive specific therapies.A previously published dataset was used to evaluate gene expression profiles of different NSCLC subtypes. A moderated two-sample t-test was used to identify differentially expressed genes between all tumor samples and cancer-free control tissue, between SCC samples and AC/BC samples and between stage I tumor samples and all other tumor samples. Gene expression microarray measurements were validated using qRT-PCR.Bayesian regression analysis and Kaplan-Meier survival analysis were performed to determine metagenes associated with survival. We identified 599 genes which were down-regulated and 402 genes which were up-regulated in NSCLC compared to the normal lung tissue and 112 genes which were up-regulated and 101 genes which were down-regulated in AC/BC compared to the SCC. Further, for stage Ib patients the metagenes potentially associated with survival were identified.Genes that expressed differently between normal lung tissue and cancer showed enrichment in gene ontology terms which were associated with mitosis and proliferation. Bayesian regression and Kaplan-Meier analysis showed that gene-expression patterns and metagene profiles can be applied to predict the probability of different survival outcomes in NSCLC patients.

NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive

“…Defining the bandwidth of the genomic regulation of neoplasia requires the simultaneous assessment of numerous parameters that circumscribe diverse aspects of tumor biology and facilitate the ‘framing' of clinical behavior [44,45,46]. Numerous successful applications of this principle have advanced the disease management of neoplasia in other sites including breast, liver, colon, prostate and lung cancer [44,47,48,49,50]. …”

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

“…The detailed analysis of other neoplastic diseases has led to the recognition that evaluation of monoanalyte secretory products (exocytotic or secreted proteins) alone fails to adequately describe the diversity of neoplastic pathobiology ( 56 ). Thus, complex analytic strategies measuring diverse regulators of neoplastic cell biology interfaced with mathematical algorithms to facilitate interpretation have been developed for breast, lung and hematological malignancies ( 57 , 58 , 59 , 60 ). Therefore, a key unmet need that remains is the development of a clinically applicable, multianalyte biomarker that captures NEN behavior and can be used to guide clinical management strategies.…”

MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A∗0201 alleles

“…In a previous study MAGEA10 was found to be one of 3 top genes, which was decisive for 1000 days' survival, and may indicate a better prognosis [22]. With the continuation of the array analysis we found that the MAGEA10 gene was expressed in 26% of Estonia NSCLC patients only, and MAGEA10-derived peptide-specific CTL were reported to be induced from the peripheral blood mononuclear cells in several cohorts [34,35].…”

“…The MAGE genes for analysis of gene expression were from a microarray dataset with an initial 85 lung tumor samples and 21 adjacent cancer-free lung samples of non-small cell lung cancer (NSCLC) patients, and the tumor characteristics files, which were previously reported [22]. The MAGE genes' methylation data was retrieved from a dataset of Illumina methylation 450 k chip analysis, but with the same panel of NSCLC samples used in the gene expression array [23].…”